Epidermal Growth Factor Receptor (Egfr) and Abcg2 Polymorphisms and Treatment Outcome in the Randomized Phase III Torch Trial in Advanced Non-Small Cell Lung Cancer (Nsclc) Patients
Geoffrey Liu(Princess Margaret Cancer Centre), Francesco Perrone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Massimo Di Maïo(University of Siena), C. Butts(University of Alberta), Ciro Gallo(University of Campania "Luigi Vanvitelli"), Mario Spatafora(Ospedale Vincenzo Cervello), Dangxiao Cheng(Ontario Institute for Cancer Research), Roberto Bianco(Federico II University Hospital), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Vincenzo Adamo(University of Messina), Adolfo Favaretto(Istituto Oncologico Veneto), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Ming‐Sound Tsao(Kumamoto University), Zijun Chen(Ontario Institute for Cancer Research), Richard Gregg, Raffaele Costanzo, R. Feld(Princess Margaret Hospital), Simona Signoriello(University of Campania "Luigi Vanvitelli"), Rafal Wierzbicki(King Faisal Specialist Hospital & Research Centre), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 0
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k